New weight-loss shot appears to outperform other obesity drugs on market Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs The Guardian - US · May 21
Super Ozempic? New weight-loss drug sees even better results in recent study Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery The Independent UK · May 21
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand. MarketBeat · May 20
Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies The Guardian - US · May 19
This Hot Weight-Loss Drug Stock May Be a Surprise Challenger The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely. Barchart · May 14
Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion… The Economic Times · May 12
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits. MarketBeat · May 7
Do Wall Street Analysts Like Eli Lilly Stock? While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. Barchart · May 6
Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly The Independent UK · May 6
Wegovy maker Novo Nordisk boosted by successful weight loss pill launch The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly. Evening Standard · May 6
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo. MarketBeat · May 1
Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s. Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart. Barchart · May 1
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy? Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge. Barchart · Apr 30
Should You Buy the Dip in Eli Lilly Stock Today? Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today. Barchart · Apr 27
International Business Times · Apr 20 Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.
Axios · Apr 17 Indiana, Eli Lilly to partner to bring nuclear power to the state Nuclear is seen as key to AI energy needs, but it's years away from large-scale viability.
The Times of India · Apr 17 UAE introduces first-ever weight loss pill Foundayo, here’s how much it may cost and where to get it The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026,…
The Independent UK · Apr 15 FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems
Barchart · Apr 4 The Next Big AI Winner Might Not Be a Tech Company Lilly’s AI push shows how non-tech firms can dominate the next wave.
The Independent UK · Apr 2 Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies
Barchart · Apr 2 Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy? Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.
MarketBeat · Apr 2 Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.
The Independent UK · Apr 2 Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable IN FULL
Barchart · Apr 1 Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here? Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.
The Guardian - US · Apr 1 US approves new oral weight-loss pill developed by Eli Lilly Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy